Bausch Health Companies stock kpis
Revenue by Segment
Breaks down sales across product lines, businesses, or regions to show which areas drive top-line growth and which are declining. Identifies concentration risk when revenue depends on a few segments and points to segments that offer the most upside if management can sustain or accelerate growth.
Bausch + Lomb is the dominant, consistent growth engine underpinning the company’s improved margins and cash generation, while Salix (Xifaxan) provides powerful incremental uplift but carries a binary exclusivity risk; Solta’s recent acceleration is a high‑margin integration win that helped management raise guidance. The Diversified bucket remains the weak spot and can mute consolidated gains. Management’s raise reflects real H1 momentum, but watch H2 gross‑to‑net accruals, Aplenzin LOE and Medicaid/340B erosion — and the Xifaxan IP outcome — for potential downside to that momentum.
BHC Revenue by Segment
| Date | International | Salix | Solta Medical | Diversified | Bausch Lomb |
|---|---|---|---|---|---|
| Sep 30, 2026 | $299.00M | $831.00M | $165.00M | $271.00M | $1.38B |
| Jun 30, 2026 | $305.00M | $758.00M | $176.00M | $219.00M | $1.39B |
| Mar 31, 2026 | $285.00M | $639.00M | $171.00M | $185.00M | $1.24B |
| Dec 31, 2025 | $306.00M | $693.00M | $137.00M | $255.00M | $1.41B |
| Sep 30, 2025 | $286.00M | $716.00M | $140.00M | $258.00M | $1.28B |
| Jun 30, 2025 | $278.00M | $627.00M | $128.00M | $219.00M | $1.28B |
| Mar 31, 2025 | $262.00M | $542.00M | $113.00M | $205.00M | $1.14B |
| Dec 31, 2024 | $279.00M | $634.00M | $138.00M | $228.00M | $1.28B |
| Sep 30, 2024 | $291.00M | $642.00M | $112.00M | $269.00M | $1.20B |
| Jun 30, 2024 | $276.00M | $558.00M | $102.00M | $251.00M | $1.22B |
| Mar 31, 2024 | $265.00M | $499.00M | $88.00M | $202.00M | $1.10B |
| Dec 31, 2023 | $290.00M | $583.00M | $103.00M | $259.00M | $1.17B |
| Sep 30, 2023 | $275.00M | $614.00M | $83.00M | $259.00M | $1.01B |
| Jun 30, 2023 | $259.00M | $557.00M | $88.00M | $228.00M | $1.03B |
| Mar 31, 2023 | $247.00M | $496.00M | $73.00M | $197.00M | $931.00M |
| Dec 31, 2022 | $261.00M | $581.00M | $99.00M | $256.00M | $996.00M |
| Sep 30, 2022 | $250.00M | $544.00M | $72.00M | $238.00M | $942.00M |
| Jun 30, 2022 | $233.00M | $501.00M | $57.00M | $235.00M | $941.00M |
| Mar 31, 2022 | $244.00M | $464.00M | $72.00M | $249.00M | $889.00M |
| Dec 31, 2021 | $276.00M | $559.00M | $89.00M | $271.00M | $1.00B |
| Sep 30, 2021 | $271.00M | $527.00M | $74.00M | $290.00M | $949.00M |
| Jun 30, 2021 | $313.00M | $516.00M | $73.00M | $264.00M | $934.00M |
| Mar 31, 2021 | $306.00M | $472.00M | $72.00M | $296.00M | $881.00M |
